SFC / Shutterstock.com
In light of the US Supreme Court’s ruling in Akamai v Limelight, Marsha Rose Gillentine, Rebecca Hammond and Robert Millonig suggest drafting strategies for personalised medicine patents to avoid the ‘divided infringement’ pitfalls.
The rest of this article is locked for subscribers only. Please login to continue reading.
If you don't have a login, you will need to purchase a subscription to gain access to this article, including all our online content. Please use this link and follow the steps.
For multi-user price options, or to check if your company has an existing subscription to us that we can add you to for FREE, please email Atif Choudhury at email@example.com
patents; pharmaceuticals; Akamai v Limelight; personalised medicine